Skip to content

Pertuzumab #
Find similar titles

Pertuzumab (also called 2C4, trade name Perjeta) is a Monoclonal antibody marketed by Genentech for the treatment of HER2+ Breast cancer, in combination with Trastuzumab and Docetaxel.

By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.

Incoming Links #

Related Medical Scholarly Articles #

Suggested Pages #